Quality Statement

Pacific Biosciences is committed to providing high-quality products that meet customer expectations and comply with regulations. We will achieve these goals by adhering to and maintaining an effective quality-management system designed to ensure product quality, performance, and safety.


Image Use Agreement

By downloading, copying, or making any use of the images located on this website (“Site”) you acknowledge that you have read and understand, and agree to, the terms of this Image Usage Agreement, as well as the terms provided on the Legal Notices webpage, which together govern your use of the images as provided below. If you do not agree to such terms, do not download, copy or use the images in any way, unless you have written permission signed by an authorized Pacific Biosciences representative.

Subject to the terms of this Agreement and the terms provided on the Legal Notices webpage (to the extent they do not conflict with the terms of this Agreement), you may use the images on the Site solely for (a) editorial use by press and/or industry analysts, (b) in connection with a normal, peer-reviewed, scientific publication, book or presentation, or the like. You may not alter or modify any image, in whole or in part, for any reason. You may not use any image in a manner that misrepresents the associated Pacific Biosciences product, service or technology or any associated characteristics, data, or properties thereof. You also may not use any image in a manner that denotes some representation or warranty (express, implied or statutory) from Pacific Biosciences of the product, service or technology. The rights granted by this Agreement are personal to you and are not transferable by you to another party.

You, and not Pacific Biosciences, are responsible for your use of the images. You acknowledge and agree that any misuse of the images or breach of this Agreement will cause Pacific Biosciences irreparable harm. Pacific Biosciences is either an owner or licensee of the image, and not an agent for the owner. You agree to give Pacific Biosciences a credit line as follows: "Courtesy of Pacific Biosciences of California, Inc., Menlo Park, CA, USA" and also include any other credits or acknowledgments noted by Pacific Biosciences. You must include any copyright notice originally included with the images on all copies.


You agree that Pacific Biosciences may terminate your access to and use of the images located on the PacificBiosciences.com website at any time and without prior notice, if it considers you to have violated any of the terms of this Image Use Agreement. You agree to indemnify, defend and hold harmless Pacific Biosciences, its officers, directors, employees, agents, licensors, suppliers and any third party information providers to the Site from and against all losses, expenses, damages and costs, including reasonable attorneys' fees, resulting from any violation by you of the terms of this Image Use Agreement or Pacific Biosciences' termination of your access to or use of the Site. Termination will not affect Pacific Biosciences' rights or your obligations which accrued before the termination.

I have read and understand, and agree to, the Image Usage Agreement.

I disagree and would like to return to the Pacific Biosciences home page.

Pacific Biosciences

PacBio and ARUP Laboratories Collaborate in a Study to Improve Rare Disease Diagnosis

Thursday, November 18, 2021

Whole genome HiFi sequencing will be used on unexplained rare disease cases to evaluate if it can identify variants not readily detectable by short-read sequencing

MENLO PARK, Calif., Nov. 18, 2021 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, and ARUP Laboratories announced today they are collaborating on a study intended to evaluate whether the solve rate for rare disease cases can be increased.

ARUP Laboratories has purchased a PacBio Sequel IIe system for use in the Utah NeoSeq Project. The project, launched in early 2020, leverages an accelerated sequencing and analysis pipeline intended to provide a genetic diagnosis for patients in the neonatal intensive care unit (NICU) in less than a week. By incorporating the Sequel IIe in the study, the team hopes to demonstrate the potential of long-read HiFi sequencing technology to identify variants in areas of the genome that are difficult to sequence with short-read sequencing technologies and, ultimately, increase diagnostic yield for rare disease cases.

Currently, the cause of more than half of rare disease cases worldwide remains unexplained. Using short-read whole genome sequencing (WGS), the lab’s current diagnostic yield for rare disease is about 30% to 50%. The study will explore the use of HiFi WGS, which provides more comprehensive, accurate, and high-definition coverage of hard-to-read regions in the human genome, to determine if it can identify variants, both small and structural, that were not readily detectible by short-read WGS. Additionally, ARUP Laboratories is seeking to develop clinical assays for areas that are difficult to sequence with short-read sequencing technologies, such as repeat expansions and pseudogenes.

“Our team at ARUP Laboratories knows that each sample represents a patient, and we want to do everything that we can to provide every patient who comes to us with a diagnosis,” said Hunter Best, PhD, Medical and Scientific Director of Genomics, ARUP Laboratories. “With the incorporation of HiFi WGS in the study, we believe that we will be able to obtain more insight into the samples we receive, ultimately helping our clients and their patients find answers.”

The initial phase of the study uses HiFi WGS on those samples already sequenced with short-read technology, but without a resulting diagnosis. The goal is to wrap up this phase of the project in the first quarter of 2022. Should the initial phase of the study be successful, the project will explore using HiFi WGS as a frontline diagnostic tool for rare and inherited disorders.

“PacBio continues this march of technology evolution, and we anticipate that ultimately more than half, and perhaps up to two-thirds, of unsolved rare disease cases could be explained through HiFi sequencing,” said Jonas Korlach, PhD, Chief Scientific Officer at PacBio. “We are thrilled to be collaborating with ARUP Laboratories to help them with a study designed to find answers for patients with rare diseases. We believe that high-quality WGS is the future of medicine and that this collaboration will be one of many impactful demonstrations.”

To learn more about the benefits of HiFi WGS in rare disease, visit www.pacb.com/rare-disease.

About PacBio
Pacific Biosciences of California, Inc. (NASDAQ: PACB), is empowering life scientists with highly accurate long-read sequencing. The company’s innovative instruments are based on Single Molecule, Real-Time (SMRT®) Sequencing technology, which delivers a comprehensive view of genomes, transcriptomes, and epigenomes, enabling access to the full spectrum of genetic variation in any organism. Cited in thousands of peer-reviewed publications, PacBio® sequencing systems are in use by scientists around the world to drive discovery in human biomedical research, plant and animal sciences, and microbiology. For more information, please visit www.pacb.com and follow @PacBio.

PacBio products are provided for Research Use Only. Not for use in diagnostic procedures.

About ARUP Laboratories
Founded in 1984, ARUP Laboratories is a leading national reference laboratory and a nonprofit enterprise of the University of Utah and its Department of Pathology. ARUP offers more than 3,000 tests and test combinations, ranging from routine screening tests to esoteric molecular and genetic assays. ARUP serves clients across the United States, including many of the nation’s top university teaching hospitals and children’s hospitals, as well as multihospital groups, major commercial laboratories, group purchasing organizations, military and other government facilities, and major clinics. In addition, ARUP is a worldwide leader in innovative laboratory research and development, led by the efforts of the ARUP Institute for Clinical and Experimental Pathology®. ARUP is ISO 15189 CAP accredited.

Forward-Looking Statements
This press release may contain “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995, including statements relating to future availability, uses, accuracy, advantages, quality or performance of, or benefits or expected benefits of using, PacBio products or technologies, the suitability or utility of such products or technologies for particular applications or projects, including in connection with the Utah NeoSeq Project, potential increases in variant detection, rare disease answers, solve rates and diagnostic yields in the Utah NeoSeq Project in particular and rare disease research in general, use of PacBio technology in the development of clinical or diagnostic assays, anticipated timing to complete the Utah NeoSeq Project, including phases thereof, the potential future use of WGS in medicine, and other future events. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, changes in circumstances and other factors that are, in some cases, beyond PacBio’s control and could cause actual results to differ materially from the information expressed or implied by forward-looking statements made in this press release. Factors that could materially affect actual results can be found in PacBio’s most recent filings with the Securities and Exchange Commission, including PacBio’s most recent reports on Forms 8-K, 10-K, and 10-Q, and include those listed under the caption “Risk Factors.” PacBio undertakes no obligation to revise or update information in this press release to reflect events or circumstances in the future, even if new information becomes available.

PacBio Contacts

Todd Friedman
+1 (650) 521-8450

Kathy Lynch

ARUP Contact
Jennifer Dobner

Press Release

PacBio Grants Equity Incentive Award to New Employee

Friday, December 3, 2021


Visit our blog »